Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW’s Guide to Recommend Against Prescribing Antibacterials for Colds, Diarrhea
March 8, 2017
- Tap Real-World Data for Optimal Use of High-Priced Meds: MHLW Bureau Chief
March 7, 2017
- 3 Kansai Medico Pharmacies Slapped with Biz Improvement Order over Fake Harvoni
March 7, 2017
- MHLW to Update Its Generic Roadmap in Line with Govt Target: Official
March 7, 2017
- PMDA Certified as APEC’s Training Center of Excellence for Regulatory Science
March 6, 2017
- Official Raw Plasma Prices for FY2017 Virtually Flat: MHLW Panel
March 6, 2017
- Panel OKs Orphan Designations for Olaparib, Inotuzumab Ozogamicin
March 6, 2017
- Opdivo Approval for Head and Neck Cancer Expected in Late March-Early April
March 6, 2017
- MHLW Advisory Committee OKs Ninlaro, Sovaldi for Genotypes 3-6
March 6, 2017
- MHLW OKs Add’l Indications for Revlimid, Other Drugs
March 3, 2017
- Orphan Status Dropped for 3 Drugs, Designation Given to Canakinumab
March 3, 2017
- Industry Reps Call for Early Discussions on Inclusion of Vaccines in Public Vaccination Programs: Hearings
March 3, 2017
- MHLW Advisory Panel Backs Shionogi’s Pediatric ADHD Drug
March 3, 2017
- New CEFP Working Group on Assessment and Analysis Launches Discussions
March 2, 2017
- Non-Partisan Lawmaker Group on Healthcare Boots Up, Plans Fortnightly Hearings
March 2, 2017
- MHLW to Tap NCCHD Database to Improve Pediatric Drug Use Environment
March 2, 2017
- Conduct Surprise Inspections on Wholesalers/Pharmacies by March-End, MHLW Asks Pref. Authorities
March 2, 2017
- MHLW OKs 53 NMEs in 2016
March 2, 2017
- 7 Products Including iPS Cell-Derived Product Receive Sakigake Review Status in the Second Round of Designations
March 2, 2017
- MHLW Summons NHK, MSD over Misleading TV Program
February 28, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…